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Therapeutic effects of dietary flavonoids have been attributed mainly to their antioxidant capacity. Xanthohumol (1), a
prominent flavonoid of the hop plant, Humulus lupulus, was investigated for its antioxidant potential and for its effect
on NF-κB activation. To examine the biological relevance of 1, a hepatic ischemia/reperfusion model was chosen as a
widely accepted model of oxidative stress generation. The impact of 1 on endogenous antioxidant systems, on the
NF-κB signal transduction pathway as well as on apoptotic parameters, and on hepatic tissue damage was evaluated.
Compound 1 markedly decreased the level of reactive oxygen species in vitro. Furthermore, levels of enzymatic and
nonenzymatic antioxidants were restored after pretreatment in postischemic hepatic tissue, and lipid peroxidation was
attenuated. NF-κB activity was reduced in vitro as well as in hepatic tissue after ischemia/reperfusion upon pretreatment
with 1. In addition, the phosphorylation of Akt was markedly inhibited. Surprisingly, 1 decreased the expression of the
antiapoptotic protein Bcl-X and increased caspase-3 like-activity, a proapoptotic parameter. Moreover, hepatic tissue
damage as well as TNF-R levels increased in xanthohumol-pretreated liver tissue after ischemia/reperfusion. In summary,
xanthohumol did not protect against ischemia/reperfusion injury in rat liver, despite its antioxidant and NF-κB inhibitory
properties.
Several dietary polyphenols, which are mainly found in fruits,
vegetables, tea, grains, and legumes, have gained interest due to
their health benefits and their protective effects in different human
disease models.1-3 Flavonoids are the most widely distributed group
of plant polyphenolics. Their beneficial effect is attributed primarily
to their role as antioxidants, which is assumed to be associated
with their polyphenolic structure, enabling them to chelate metal
ions and to scavenge singlet oxygen as well as reactive oxygen
species (ROS).4,5 The latter are implicated in direct injury to cells
as well as in the generation of various acute-phase proteins and in
the activation of redox-sensitive transcription factors when the
endogenous redox degrading system is overstressed.6 Importantly,
treatment with flavonoids reduces ROS-mediated cellular alterations
and prevents oxidative tissue injuries.7,8
Xanthohumol (1) is the principal prenylated flavonoid of the hop
plant (Humulus lupulus L.; Cannabaceae), which constitutes ap-
proximately 82-89% of the total amount of prenylated flavonoids
of different hop varieties.9 The only dietary source of 1 is beer,
since hops are added for bitterness and the typical aroma. In recent
years, 1 has attracted considerable interest, as it was identified as
a broad-spectrum anticancer and chemopreventive compound, which
is assumed to be in particular due to its diverse antioxidant and
free-radical-scavenging properties.10-13
However, ROS are assumed to play an important role in various
pathological conditions apart from cancer, such as the ischemia/
reperfusion injury (IRI) of the liver.14 Hepatic IRI contributes to
the morbidity and mortality associated with shock, transplantation,
and liver surgery.15,16 It has been generally accepted as a system
for oxidative stress in vivo.17 Therapeutic interventions by treatment
with antioxidants or gene therapy using viral and nonviral vectors
containing genes of endogenous antioxidants have been shown to
improve hepatic tissue injury.18,19 Along with ROS, the redox-
sensitive transcription factor nuclear factor κB (NF-κB) has been
reported to play a pivotal role in the ischemia/reperfusion (IR)
model, leading to the expression of proinflammatory cytokines and
cell adhesion molecules, resulting in neutrophil-mediated inflam-
mation following tissue injury.15,20,21 Interestingly, NF-κB inhibi-
tion was attributed to antioxidant and radical-scavenging approaches
and has been claimed to reduce injury following hepatic IR.19,22,23
Thus, an interdependency of oxidative stress and NF-κB activation
with tissue injury in hepatic IR is generally accepted.18,24,25
These data have prompted us to elucidate the role of 1 in a
complex oxidative stress driven injury model. The aim of this study
was to investigate the impact of the dietary flavonoid xanthohumol
on the hepatic IRI and to understand the underlying molecular
mechanisms.
Results and Discussion
Impact of Xanthohumol (1) on ROS Production in a Cell-
Free (Xanthine/Xanthine Oxidase) and a Cellular System
(H2FDA). Structure-activity relationship studies of flavonoids have
shown that their antioxidant activities are attributed mainly to certain
hydroxy substituents in the A- and B-rings and the 2,3-double bond
conjugated with the 4-oxo function.4 Flavonoid 1 displays these
structural specificities, and, indeed, the high antioxidant potential
of this compound was recently published in vitro.12,13 The ability
of compound 1 to scavenge superoxide radical was evaluated by
chemiluminescence measurement using a xanthine/xanthine oxidase
assay. Compound 1 (Figure 1A,B) showed a dose-dependent
reduction in ROS production with an IC50 of 15 µM. Intracellular
response to oxidative challenge (H2O2) was measured by loading
HEK 293 cells with 20 µM dihydrofluorescein diacetate (H2FDA).
After penetrating the cell membrane, ester groups of H2FDA are
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cleaved by esterases, which leads to the formation of dihydrofluo-
rescein, a ROS-sensitive fluorescence dye. A 40 µM concentration
of 1 (Figure 1C) showed significant fluorescence reduction (to 71.9
( 9.2%), in comparison to the corresponding control. Treatment
with the well-established antioxidant N-acetylcysteine (NAC; 1
mM), which served as positive control, attenuated fluorescence to
46.2 ( 14.9%. The MTT test with HEK 293 cells showed that 1 is
not cytotoxic up to concentrations of 300 µM (Figure 1D).
Therefore, the reduction of ROS production in the cellular assay
cannot be attributed to cytotoxicity.
Antioxidant Parameters and Indicators of Oxidative Stress
in Hepatic Tissue Pretreated with Xanthohumol (1) Prior
to Ischemia and Reperfusion. Since antioxidant activity has been
found to be, at least in part, responsible for the broad-spectrum
anticancer and chemopreventive properties of 1, we were interested
in evaluating the potential of xanthohumol in another pathophysi-
ological system, which is driven by oxidative stress such as the
hepatic ischemia and reperfusion. Treatment with the flavonoid rutin
in hepatic ischemia/reperfusion injury has already been demon-
strated to be beneficial in preventing oxidative damage, hence
reducing liver tissue injury.26 Similar studies have confirmed these
results for resveratrol, epigallocatechin gallate, quercetin, and
anthocyanins, respectively.7,27-29 In our study, IR leads to signifi-
cant reductions of enzymatic activity of SOD in liver tissue. This
effect is abolished after administration of 2.26 mM 1 (Figure 2A).
Thus, we show herein for the first time that xanthohumol (1) is
able to restore the endogenous ROS scavenging enzyme superoxide
dismutase (SOD) in IRI. SOD accounts for detoxification of a major
proportion of the highly reactive superoxide anion radical in the
liver tissue, and the administration of SOD derivatives in the hepatic
IR process has been demonstrated previously to be protective.30
We demonstrate that the activity of the nonenzymatic redox-
degrading antioxidant GSH was reduced significantly in animals
subjected to IR, but kept unchanged by xanthohumol (2.26 mM)
treatment (Figure 2B). Again, exogenous administration of the
nonenzymatic antioxidant GSH in different IR models has been
shown to have beneficial effects regarding hepatic tissue injury.15,31
Consequently, we determined lipid peroxidation as a marker for
oxidative stress by quantifying the 8-isoprostane content. An
increase in the 8-isoprostane levels was observed in animals
subjected to IR. This effect was decreased significantly after
treatment with 1 (2.26 mM) prior to IR (Figure 2C). Thus,
xanthohumol has a strong antioxidant potential in the complex
hepatic IR model.
Effect of Xanthohumol (1) on NF-KB Activity in Vitro
(Reporter Gene Assay) and in Vivo (EMSA). Along with ROS,
the redox-sensitive transcription factor NF-κB has been shown to
be relevant for hepatic IRI, as it up-regulates the expression of
different proinflammatory genes and correlates with the severity
of tissue damage.21,32 Treatment of rats prior to IRI with green tea
extract, which contains high levels of polyphenols, has been shown
to inhibit NF-κB binding activity in this model.23 Here, we
demonstrate dose-dependent inhibitory effects of 1 (IC50 35 µM)
in a TNF-R-induced NF-κB-dependent reporter-gene assay (Figure
3A). PDTC served as a well-established inhibitor of NF-κB activity.
To investigate the impact of 1 on NF-κB DNA-binding activity
in the liver after IR, the electrophoretic mobility shift assay (EMSA)
was performed with nuclear extracts of respective tissue samples.
As shown in Figure 3B, NF-κB activity of the liver tissue increased
greatly after 6 h of cold ischemia followed by reperfusion of 150
min when compared to untreated liver tissue. Animals treated with
2.26 mM 1 prior to the ischemic period revealed attenuated DNA
binding activity of NF-κB.
Impact of Xanthohumol (1) on Expression of Phospho-
rylated Akt in Rat Liver after IR. The Akt pathway is an
important upstream activator of the NF-κB pathway and has been
described previously to be repressed by 1.9 Interestingly, inhibition
of Akt phosphorylation was achieved by pretreatment with 1 in
the liver as well. These results suggest that NF-κB inhibition by 1
in cold IR might be, at least in part, regulated by an Akt inhibition.
Figure 1. Antioxidant activity of xanthohumol (1) in a cell-free
and in a cellular system. (A) Time course of ROS inhibition in a
cell-free xanthine/xanthine-oxidase model depending on different
concentrations of 1 in comparison to the control. (B) Area under
the curve (AUC) of light emission from chemiluminescent reaction
for different concentrations of 1 in comparison to controls (100%),
in a cell-free xanthine/xanthine-oxidase model. Data are presented
as mean ( SEM (n ) 9, *p < 0.05 vs control, Student’s t test). (C)
Fluorescence was measured in H2FDA loaded HEK 293 cells
pretreated with 40 µM XN prior to stimulation with H2O2.
Significance was calculated at a 95% concentration interval in
comparison to the corresponding controls (*). Data are presented
as mean ( SEM (n ) 4, *p < 0.05 vs control, Student’s t test).
The antioxidant N-acetylcysteine (NAC) was used as positive
control. (D) Cytotoxicity of 1 was measured after incubation with
10 to 300 µM for 3 h by the MTT assay in HEK 293 cells. No
cytotoxicity was found for any concentration tested.
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It has been shown that phosphorylation of Thr-308 is the main
activating event of Akt, although phosphorylation of both domains
(Thr-308 and Ser-473) might be necessary for full activation of
Akt.33 Xanthohumol (1) (2.26 mM) pretreatment abrogated the
phosphorylation of both Ser-473 and Thr-308, respectively, in
comparison to solvent-treated animals after IR (Figure 3C). The
quantitative densitometric analysis of both phosphorylation sites
showed no effects of ischemia and reperfusion per se, but underlines
the inhibition of both types of phosphorylation by 1 (Figure 3D).
Effect of Xanthohumol (1) on Expression of Antiapoptotic
Proteins and on Caspase Activity in Rat Liver after IR. Akt
is described as a typical antiapoptotic kinase involved in IRI,33 as
it inactivates proapoptotic proteins such as Bad and subsequently
activates antiapoptotic proteins of the Bcl-2 family.33 Since we have
described previously an antiapoptotic action of Akt in the liver,21
and since Akt has been described to induce an antiapoptotic pattern
of proteins of the Bcl-2 family,34 we took a closer look at anti-
and proapoptotic proteins in this context. The proteins of the Bcl-2
family exert either pro- or antiapoptotic effects. Bcl-xl is one of
the antiapoptotic proteins in this family.35 Pretreatment with 1 (2.26
mM) reduced the protein level of Bcl-xl in livers subjected to IR
(Figure 4A). Thus, we could demonstrate that 1-mediated Akt
inhibition correlates with down-regulation of the levels of the
antiapoptotic protein Bcl-xl. This is well in accordance with
previous findings with xanthohumol in nonhepatic cells.36,37
Caspases are intracellular cysteine proteases that mediate inflam-
mation and cell death. Caspase-3 in particular is the main effector
molecule of apoptosis and a selective inhibitor in the IR process
that effectively reduces hepatic IRI.38 Intrahepatic caspase-3-like
activity was measured after IR, as caspase-3 activation plays a
pivotal role in tissue damage. The hepatic caspase activity in IR-
treated animals was significantly increased in comparison to
nonischemic animals. Interestingly, 1 (2.26 mM)-treated animals
showed a significant increase in hepatic caspase activity (Figure
4B).
Impact of Xanthohumol (1) on Liver Injury. The perfusates
were collected during the reperfusion period, and liver enzymes
(AST + ALT), a parameter for hepatocyte damage, as well as LDH
(a more general indicator of cytotoxicity) were measured. Pretreat-
ment with 1 showed a tendency toward increased AST and ALT
activity during late reperfusion in perfusate compared to solvent-
treated animals after IR (Figures 5A,B). Thus, surprisingly, hepatic
tissue damage was not improved by pretreatment with 1, despite
its antioxidant and NF-κB inhibitory activities. Instead, hepatic
tissue injury was slightly increased, as also shown by increased
levels of LDH (Figure 5C). Since these effects are only significant
at 150 min of reperfusion, an acute and direct cytotoxic effect of
the relatively high concentrations of 1 during ischemia can be
excluded. The levels of TNF-R (a cytokine that is partly regulated
by NF-κB) in the perfusates show an increase over time, but are
not significantly influenced by 1 (Figure 5D).
These results were unexpected, as antioxidant activities of
flavonoids and general NF-κB inhibition are assumed to be
protective in several oxidative stress driven diseases and, in
particular, hepatic IRI. To this end, the role of NF-κB and Akt in
IR of the liver has to be examined carefully, requiring a detailed
interpretation of the data obtained. First, the inhibition of the protein
kinase Akt must be interpreted critically regarding these contrary
results. Apart from its activation of NF-κB, Akt regulates cell
survival, cell cycle, and proliferation.39 Interestingly, constitutively
active Akt has been shown to be beneficial during hepatic IR,
although long-term Akt activation has potential deleterious effects
as well.40 Moreover, our research group has demonstrated that
preconditioning with R-lipoic acid induces temporary Akt phos-
phorylation and in turn reduces tissue injury after IR.21 Thus,
general Akt inhibition as presented here might have a harmful
potential following IR. Second, the role of NF-κB in the liver has
to be carefully examined during IRI. It has been assumed that NF-
κB in the liver displays an ambiguous role, depending on the cell
type addressed. NF-κB activation in hepatocytes is essential for
Figure 2. Effect of xanthohumol (1) on oxidative defense and stress
parameters in IR-treated hepatic tissue. (A) SOD activity after
treatment with 2.26 mM 1 or solvent, respectively, prior to IR.
Livers of untreated animals served as control (100%). Data are
presented as mean ( SEM (n ) 3, #p < 0.05 vs control, *p < 0.05
vs solvent, Student’s t test). (B) GSH level after treatment with
2.26 mM 1 or solvent, respectively, of livers subjected to IR. Livers
of untreated animals served as control (100%). Data represent means
( SEM of triplicates, containing three animals per group (# p <
0.05 vs control, Student’s t test). (C) 8-Isoprostane level after
treatment with 2.26 mM 1 or solvent, respectively, of livers
subjected to IR. Livers of untreated animals served as control
(100%). Data are presented as mean ( SEM (n ) 3, #p < 0.05 vs
control, *p < 0.05 vs solvent, Student’s t test).
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Figure 3. Impact of xanthohumol (1) on the NF-κB signal transduction pathway. (A) NF-κB promoter activity of HEK 293 cells
treated with different concentrations of 1 prior to TNF-R stimulation. NF-κB activity of cells treated with solvent were set at 100%,
and PDTC-treated cells were used as a positive control. Data are presented as mean ( SEM (n ) 3, *p < 0.05 vs control, Student’s
t test). (B) NF-κB binding activity was determined in liver tissue by EMSA. Liver homogenates were treated with 2.26 mM 1 or
solvent, respectively, prior to IR. Liver tissue of untreated animals served as control. One representative gel shift experiment is
shown (n ) 3). (C) Hepatic protein levels of phosphorylated Akt (Ser-473, upper panel; Thr-308, lower panel) and -actin by WB
analysis of livers treated with 2.26 mM 1 or solvent, respectively, prior to IR. Liver tissue of untreated animals served as control.
One representative blot is shown (n ) 3). (D) Quantitative densitometric evaluation of phosphorylated Akt (Ser-473, left; Thr-308,
right panel), depicted in part C (n ) 3).
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hepatocyte regeneration, as it exerts antiapoptotic properties.41 In
contrast, the resident liver macrophages, the Kupffer cells, are
presumed to be largely responsible for the excessive inflammatory
response induced by IRI.15,20 Therefore, a selective inhibition of
NF-κB in the Kupffer cells may be a more promising approach.41,42
Since it is unlikely that 1 inhibits NF-κB selectively in Kupffer
cells, a cell-type-independent and predominant NF-κB inhibition
in hepatocytes by xanthohumol might not result in hepatic tissue
protection, despite its antioxidant properties.
In conclusion, these results indicate that the flavonoid xantho-
humol (1) from H. lupulus does not improve tissue injury after
hepatic ischemia and reperfusion despite its extensive antioxidant
activities. Thus, antioxidative properties of natural polyphenols do
not necessarily warrant beneficial therapeutic usage. To this end,
the complexity of oxidative stress-driven signaling pathways in
various organ and disease systems has to be taken into account.
Experimental Section
Synthesis of Xanthohumol (1). Compound 1 was synthesized in
pure form as recently described.43
Cell-Free System. Xanthine/Xanthine-Oxidase Assay. The chemi-
luminescence mixture was prepared immediately before analysis by
mixing 230 µL of 1 mM xanthine (Sigma Aldrich, Steinheim, Germany)
and 30 µL of a solution containing solvent (control) or different
concentrations of 1 (5-80 µM), respectively. To start the reaction, 20
µL of 1 mM luminol (Sigma Aldrich) and 20 µL of 0.5 U/mL xanthine-
oxidase (Sigma Aldrich) were injected into the mixture. Chemilumi-
nescence was measured for 100 s at 37 °C using an Orion II microplate
luminometer (Berthold Detection Systems, Pforzheim, Germany), and
the results were expressed as relative light units (RLU) or its area under
the curve (AUC).
Cell Culture. Cell Line. The human embryonic kidney cell line
293 (HEK 293; DSMZ-German collection of microorganisms and cell
cultures, ACC 305) was grown in phenol-red-free DMEM (PAA
Laboratories, Pasching, Austria), supplemented with 10% fetal calf
serum (Biochrom KG, Berlin, Germany) and 2 mM glutamine (Merck,
Darmstadt, Germany) at 37 °C and 5% CO2 in 75 cm2 tissue culture
flasks. Cells were split when reaching ca. 85-90% confluency. Cells
were washed with phosphate-buffered saline (PBS) and subsequently
detached with 0.05% trypsin/0.02% EDTA in PBS.
Dihydrofluorescein Diacetate Assay. Cells were seeded in 24-well
plates and when reaching about 85-90% confluency, treated for 2 h
with 1 (40 µM) or N-acetylcysteine (NAC, 1 mM), respectively. After
90 min, the cells were loaded additionally with 20 µM dihydrofluo-
rescein diacetate (Invitrogen, Karlsruhe, Germany) by incubation for
30 min at 37 °C in the dark. Subsequently, cells were washed and
stimulated with 1 mM H2O2 for 20 min. Fluorescence was measured
with a SpectraFluor Plus microplate reader (Tecan, Crailsheim,
Germany), using an excitation and emission wavelength of 485 and
535 nm, respectively.
MTT Assay. Cells were seeded in 24-well plates and when reaching
about 85-90% confluency, treated for 3 h with 1 at concentrations
from 10 to 300 µM. Then, 10 µL of a 5 mg/mL solution of MTT reagent
was added, and the mixture was incubated for 1 h at 37 °C. The blue
precipitate was solubilized with DMSO, and absorption was measured
at 550 nm.
NF-KB Reporter Gene Assay. HEK 293 cells were seeded at a
concentration of 4 × 106 cells/100 mm dish. The next day, cells were
transiently transfected with a plasmid containing a promoter with
repetitive NF-κB binding sites driving a firefly luciferase gene using
the Ca2+-phosphate method (p NF-κB luc plasmid, Stratagene, Heidel-
berg, Germany). Transfected cells were seeded in 24-well plates at a
concentration of 1 × 105 cells/well and grown for an additional 16 h.
Then cells were preincubated for 2 h with different concentrations of
1 (5, 10, 20, 40, and 60 µM) and subsequently stimulated with 1 ng/
mL TNF-R (Calbiochem, San Diego, CA) for 6 h. Pyrrolidine
dithiocarbamate (PDTC, 50 µM; Sigma Aldrich)-preincubated cells
served as a positive control. Finally, cells were washed with PBS and
lysed, and the NF-κB activity was measured with a commercial
luciferase assay kit (Luciferase Assay System; Promega, Mannheim,
Germany), according to the manufacturer’s instructions, using a
luminometer (AutoLumatPlus, Berthold Technologies, Bad Wildbad,
Germany).
Isolated Liver Perfusion Model. Animals. Male Sprague-Dawley
rats (6 weeks old), weighing 200-240 g, were purchased from Charles
River Laboratories (Sulzfeld, Germany) and housed in a climatized
room with a 12 h light-dark cycle. The animals had free access to
chow (Ssniff, Soest, Germany) and tap water up to the time of the
experiments. All animals received humane care in compliance with
the Principles of Laboratory Animal Care. This study was registered
with the local animal welfare committee.
Cold Ischemia and Reperfusion. After opening the abdomen by a
midline laparotomy, the bile duct, portal vein, and suprahepatic inferior
vena cava were cannulated. The livers were drained and rinsed free
from blood in situ with hemoglobin-free and albumin-free bicarbonate-
buffered Krebs-Henseleit (KH) solution (pH 7.4, 37 °C) saturated with
95% O2 and 5% CO2. Additionally, the hepatic artery, the infrahepatic
inferior vena cava, and the right kidney vein were ligated. The perfusion
medium was pumped constantly through the liver with a peristaltic
pump (Digi-staltic, Masterflex, Gelsenkirchen, Germany) in a nonre-
circulating fashion (30 mL/min). After 30 min of perfusion, livers were
flushed with 100 mL of ice-cold (4 °C) PBS solution, initiating the
cold ischemic period. After stopping the perfusion, organs were
preserved at 4 °C for 6 h. Following the period of ischemia, livers
were reperfused with KH buffer for 150 min at 37 °C with a flow rate
of 3.0-3.5 mL × min-1 × g liver. Perfusate samples were collected
and kept at -80 °C for transaminase and LDH measurement. Liver
samples were obtained at the end of the reperfusion period and were
snap-frozen in liquid nitrogen until analysis.
Treatment Protocols. For treatment of livers, 2.26 mM 1 was
dissolved in the dissolution medium (4% propylene glycol, 3% TWEEN
80 in PBS) and filled in NORM-JECT syringes (Henke Sass Wolf,
Tuttlingen, Germany). The chilled solutions (4 °C) were injected into
the portal vein right before the ischemic period. Injection of the solution
medium served as a control. This treatment with a high concentration
of 1 during cold ischemia served to simulate the conditions during organ
preservation for transplantation. The rapid washout during reperfusion
makes this high concentration necessary in order to keep up effective
levels of 1 (approximately in the µM range) in the first minutes of
reperfusion.
Glutathione Measurement. Glutathione (GSH) was measured using
the colorimetric microplate assay from Oxford Biomedical Research
(Oxford, MI). Briefly, the total GSH content of the liver tissue
Figure 4. Influence of xanthohumol (1) on anti- and proapoptotic
parameters. (A) Hepatic Bcl-xl expression by western blot analysis
of livers treated with 2.26 mM 1 or solvent, respectively, prior to
IR. -Actin expression served as loading control. Liver tissue of
untreated animals served as control. One representative blot is
shown (n ) 3). (B) Caspase-3-like activity of animals treated with
2.26 mM 1 or solvent, respectively, prior to IR. Caspase activity
of liver tissue of untreated animals (control) was set as 1. Data are
presented as mean ( SEM (n ) 3, *p < 0.05 vs control, Student’s
t test).
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homogenate is measured after reduction of DTNB [5,5′-dithiobis(2-
nitrobenzoic acid)], causing a colored ion that absorbs light at 405 nm.
The absorption is proportional to the total GSH concentration. The
results were expressed as percentage of untreated controls. Protein
content was determined using the Bradford method.44
Superoxide Dismutase Activity Assay. Superoxide dismutase
(SOD) activity was analyzed using the pyrogallol method described
by Marklund and co-workers.45 The amount of enzyme that inhibits
the autoxidation rate of pyrogallol by 50% was defined as one unit.
The results are expressed as percentage of untreated controls. Protein
content was determined using the Bradford method.44
Lipid Peroxidation. The 8-isoprostane concentration of liver
homogenates was measured using the 8-isoprostane EIA Kit from
Cayman Chemicals (Ann Arbor, MI). Briefly, the assay is based on
thecompetitionbetween8-isoprostaneandan8-isoprostane-acetylcholinesterase
conjugate. After addition of the substrate, the product of this enzymatic
reaction has a distinct yellow color and absorbs at 412 nm. The
absorption is indirectly proportional to the total 8-isoprostane content.
The results were expressed as percentage of untreated controls.
NF-KB Electrophoretic Mobility Shift Assay. Electrophoretic
mobility shift assays (EMSA) were performed as described previously
by our group.21 The consensus binding sequence used for NF-κB was
5′-AGT TGA GGG GAC TTT CCC AGG C-3′ (Promega, Mannheim,
Germany). Relative light unit (RLU) density was determined by
autoradiography using the Cyclone Phosphor Imager (Perkin-Elmer,
Dreieich, Germany).
Western Blot Analysis. Western blot analysis was performed as
described previously.21 Proteins transferred to the membrane were
identified by incubating at 4 °C overnight with primary antibodies
against Bcl-xl (Santa Cruz, Heidelberg, Germany) and phosphorylated
Akt (Ser 473 and Thr 308; Cell Signaling, Danvers, MA), followed by
incubation with a HRP-conjugated secondary goat anti-rabbit (Dianova,
Hamburg, Germany) or goat anti-mouse (Biozol, Eching, Germany)
antibody, respectively. The reactive bands were visualized employing
a chemiluminescent detection kit (ECL Plus, Amersham Pharmacia,
Uppsala, Sweden). -Actin (Millipore, Billerica, MA) or total Akt (Cell
Signaling, Danvers, MA) was used as loading control, respectively.
For densitometric quantification of the bands, a special software (Li-
Cor Biosciences, Lincoln, NE) was employed.
Caspase-3-like Activity. Caspase-3 like activity was measured as
described previously.16 Extracts were incubated with Ac-DEVD-AFC,
and the generation of AFC was determined by fluorescence measure-
ment (excitation: 385 nm; emission: 505 nm).
Transaminases. Activities of aminotransferases (alanine transferase
(ALT) and aspartate transferase (AST)), as well as LDH of the collected
perfusate were determined at different time points of the reperfusion
period by using a serum multiple analyzer (Olympus AU 2700,
Hamburg, Germany) at 37 °C by the Institute for Clinical Chemistry,
Klinikum Grosshadern, University of Munich, Germany.
TNF-r ELISA. Rat TNF-R UltraSensitive ELISA kit was obtained
from BioSource. Determination of TNF-R levels of the perfusate was
performed according to the manufacturer’s manual. The absorbance
Figure 5. Impact of xanthohumol (1) on liver tissue injury parameters and proinflammatory cytokine level. (A) Time course of ALT levels
of liver perfusates treated with 2.26 mM 1 or solvent, respectively, prior to IR. Data are presented as mean ( SEM (n ) 3). (B) Time
course of AST levels of liver perfusates treated with 2.26 mM 1 or solvent, respectively, prior to IR. Data are presented as mean ( SEM
(n ) 3). (C) Time course of LDH levels of liver perfusates treated with 2.26 mM 1 or solvent, respectively, prior to IR. Data are presented
as mean ( SEM (n ) 3). (D) TNF-R levels of liver perfusates were determined by ELISA, of 1 (2.26 mM) or solvent-treated animals,
respectively, after 60 and 120 min reperfusion. Data are presented as mean ( SEM (n ) 3).
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was measured at 450 nm using the Sunrise absorbance reader from
TECAN. Color development was proportional to the amount of rat
TNF-R in the perfusate.
Statistical Analysis. The number of experiments is indicated in the
respective figure legend. Data are expressed as mean ( SEM. Statistical
analysis was performed using the GraphPad Prism 3.03 software
(GraphPad Software Inc., San Diego, CA). Significance (*, #) was
calculated at the 95% confidence interval between indicated groups,
using an unpaired t test.
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